Spring Pulse Check: Highlights from a Dynamic Season

Life at Powerful Medical is moving at lightning speed, and we’re excited to share our recent achievements. The past few months have been dynamic and transformative, highlighted by key milestones and significant progress.

Here’s what we've been up to:

🏆 Wins and Recognitions

We Secured €7.5M in Funding from the European Innovation Council 

Selected from over 4,000 applicants and ranking in the top 0.1% of our cohort, we have been awarded a €2.5 million grant and a €5 million investment from the European Innovation Council (EIC).

As our user base is expanding rapidly, with 40,000 registered healthcare professionals and partnerships with hundreds of prestigious institutions, this financing comes at a perfect time.

“We are immensely grateful for the EIC’s recognition and support, which propels us closer to achieving our mission of saving lives on a global scale. This investment fuels our ambition to broaden our reach within the EU and pioneer entry into the US, a journey supported by early believers like Life Extension Ventures, Venture to Future Fund (backed by European Investment Bank), Zero Gravity Capital, and our partners at Civitta.”  Martin Herman, CEO of Powerful Medical.

We've been selected as a 'High-Potential Healthcare AI Startup' by Google!

We are thrilled to share that Powerful Medical has been selected for the Google Growth Academy: AI for Health program. As part of the Google for Startups initiative, this program recognizes 24 pioneering startups from across Europe, the Middle East, and Africa, all using AI to revolutionize healthcare and advance medical research.

The program kicked off this week in Paris with an in-person summit, bringing together the brightest minds in the AI healthcare space. Over the months, we will engage in workshops covering AI best practices, leadership development, responsible innovation, product design, and customer acquisition. Additionally, the program provides mentorship and access to experts across Google Research, Google Health, Verily, Fitbit, and Google DeepMind.

Our Founders Recognized as Part of the Forbes 30 Under 30 Europe List

In more fantastic news, our co-founders, Martin Herman and Robert Herman, MD, have been recognized as part of the prestigious Forbes 30 Under 30 Europe 2024 list. Chosen from thousands of candidates, their inclusion is a testament to our commitment to revolutionizing cardiac diagnostics.

Learn more on our blog:

🖥️ Product Update

PMcardio for Organizations is a robust solution that ensures accurate diagnoses and swift referrals to cardiovascular specialists by capturing and analyzing all ECG data within the organization's system.

This comprehensive solution meets the needs of diverse groups and organizations, enhancing overall care delivery and coordination. Offering secure and integrated patient management ensures effective patient triage.

Key features include:

• Certified AI ECG modules – Accurately diagnoses occlusion myocardial infarction (OMI) in patients presenting with chest pain.

• Enterprise security – Ensures data safety with the highest security, compliance, and privacy standards.

• Central report management – Grants access to all ECGs in the organization through a single admin dashboard.

• PACS / CVIS integration – Seamlessly incorporates advanced AI models into existing hospital systems and workflows.

• Organization onboarding – Encompasses a comprehensive process for entire institutions and health systems, ensuring all teams are effectively integrated and trained.

• User administration – Manages team members efficiently with user permissions that ensure the right level of access and functionality for everyone.

• Early access to advanced AI ECG diagnostics – Offers early access to experimental features like OMI explainability and new AI models in development.

Find out more on our website:

We Are Now Officially ISO 27001 Certified!

After years of adhering to the rigorous ISO27001 standards—the global benchmark for information security management—we are happy to announce that we have achieved the official ISO27001 certification. This milestone reinforces our unwavering commitment to implementing robust information security practices and safeguarding the data of our customers and partners. 

Read more on our blog:

🚀 Traction and Research Continue the Momentum

AI-Augmented Chest Pain Pathway: 37 Sites in International Validation

As we are advancing our International OMI AI Model Clinical Validation pipeline, enhancing and rigorously validating the PMcardio OMI AI ECG Model, which is currently undergoing extensive testing at 37 clinical sites distributed across 25 countries.

The research initiative encompasses the analysis of over 85,000 consecutive patients who presented with chest pain, underscoring our commitment to understanding the model’s applicability and accuracy in diverse clinical scenarios.

The key element of validation is the creation of the largest known database related to ECG analysis and patient outcomes in the context of chest pain, featuring data on nearly 100,000 individuals. 

Our aim is to build the single largest, most comprehensive, international database of patients with ACS comprising patient ECGs, lab data, cath lab data, and outcomes.

The model’s validation across more than five subpopulations within acute coronary syndrome (ACS), including out-of-hospital cardiac arrest (OHCA), demonstrates its versatility and potential applicability in various emergency care scenarios.

Expanding Our External Validations: Uniklinik Köln, Germany

The PMcardio OMI AI Model has gained further validation from esteemed global institutions, including Uniklinik Köln. Pioneers such as Dr. Sascha Macherey-Meyer and Dr. Christoph Adler led a study showcased at Germany's largest cardiology congress, the 90th DGK Annual Meeting, demonstrating outstanding diagnostic accuracy for occlusion myocardial infarction.

Read more about our ongoing international clinical validation in our blog:

Exciting News for the ESC Congress 2024 in London!

We are excited to share that our abstract, "A smartphone-based AI model to detect left ventricular systolic dysfunction on 12-lead ECG," has been accepted for presentation at the ESC Congress 2024 in London. Anthony Demolder, MD from our clinical team, will present it at the Digital Health Stage.

Stay tuned for more PMcardio news ahead of the ESC Congress!

We introduced PMcardio to the US audience at ACC 2024!

We had a great time at ACC24, organized by the American College of Cardiology! Our attendance was one of the stepping stones toward gearing up for the U.S. market. We were proud to showcase our AI-powered ECG interpretation platform, PMcardio, to our future customers in the U.S. It was also a wonderful opportunity to make new connections for potential partnerships and to meet with those we are already collaborating in our validation pilot programs.

Our expert team, including esteemed ECG specialists Dr. Steve Smith and Dr. Pendell Meyers, thought leaders in emergency medicine, showcased how our innovative technology revolutionizes diagnosing and treating acute myocardial infarctions.

Find further details on our blog:

Our CEO Took the Stage at LSI USA ‘24 Emerging Medtech Summit

At the Life Sciences Innovation (LSI) Conference, our CEO Martin Herman stole the show with a presentation that perfectly captured the essence and potential of our innovative work. Highlighting PMcardio, our AI-powered ECG interpretation platform, he emphasized our commitment to addressing cardiovascular diseases—the leading cause of death worldwide. Our mission is clear: to deliver faster, better, and unbiased expert cardiac care on a global scale.

Catch the full presentation in this video:

Closing Thoughts and Gearing Up for What's Next

As we reflect on these milestones, it's clear that life at Powerful Medical is advancing at an exhilarating pace. The recognition and support we've received fuel our unwavering commitment to revolutionizing cardiovascular healthcare. With substantial investments, prestigious awards, and continuous product advancements, we are well-positioned to broaden our impact globally.

Thank you for joining us on this remarkable journey. Stay tuned for more impactful updates soon.

About Powerful Medical

Powerful Medical is at the forefront of the AI revolution in healthcare, leading the charge against the world's leading cause of death: cardiovascular diseases. With its flagship product, the PMcardio platform, a CE-certified medical device, the deep-tech company is setting new standards in cardiac care.

The platform's unparalleled ability to diagnose 39 cardiovascular conditions from an ECG places it leagues ahead of traditional diagnostic methods. Powerful Medical is poised for substantial growth. It already has significant traction in the EU and is on the cusp of entering the US market pending FDA 510(k) approval, with multiple US pilots ongoing.

Its data-driven approach improves immediate clinical outcomes and paves the way for the future of predictive medicine. Backed by a robust research network and clinical validations, Powerful Medical is not just transforming heart care; it saves lives, one diagnosis at a time.

Guided by a commitment to excellence and innovation, CEO Martin Herman and Robert Herman, MD, a Committee Member at the European Society of Cardiology, stand at the forefront of the company's innovative mission. They are joined by experts Prof. Dr. Jozef Bartunek from the OLV Ziekenhuis Aalst-Asse-Ninove, Prof. Stephen Smith, MD, and Prof. Pendell Meyers, MD, who contribute to the development and rigorous clinical validation of PMcardio. Prof. Dr. Emanuele Barbato, President of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), adds his profound expertise to the team, further reinforcing the company's dedication to advancing cardiac care through artificial intelligence.